Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Nightstar Therapeutics (NITE) PT Raised to $36 at Wedbush
September 24, 2018 6:39 AM EDT
On Saturday, Nightstar Therapeutics plc (NASDAQ: NITE) announced that positive preliminary safety and efficacy data of NSR-RPGR from the dose escalation study in the Phase 1/2 XIRIUS trial were presented today at the EURETINA 2018 Congress.
We initiated this study last year, with the anticipation of demonstrating safety and stabilization of disease with NSR-RPGR, our codon-optimized gene therapy for XLRP, said Tuyen Ong, M.D., chief development officer of Nightstar. Based on the preliminary findings of improved visual function as measured by microperimetry, we have established early proof of concept in... More
September 24, 2018 5:42 AM EDT
BMO Capital analyst Matthew Luchini raised the price target on Nightstar Therapeutics (NASDAQ: NITE) to $41.00 (from $30.00) while maintaining a Outperform rating.
...
More
